Sumitomo Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1984-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.sunovion.com
Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 841
- Registration Number
- NCT00909779
- Locations
- 🇺🇸
C.A.R.E. Clinical Research, St. Louis, Missouri, United States
🇺🇸Neem Research Group, Inc., Columbia, South Carolina, United States
🇺🇸DCT, Sugar Land, Texas, United States
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 505
- Registration Number
- NCT00868699
- Locations
- 🇺🇸
CRI Worldwide, LLC, Philadelphia, Pennsylvania, United States
🇺🇸Mood Disorders Program-UHCMC, Cleveland, Ohio, United States
🇮🇳R.K. Yadav Memorial Mental Health & De-Addiction Hospital, Jaipur, Rajasthan, India
Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)
- Conditions
- Bipolar Depression
- Interventions
- Drug: Placebo + (lithium or divalproex)
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 348
- Registration Number
- NCT00868452
- Locations
- 🇨🇿
Clintrial, s.r.o., Praha, Czech Republic
🇮🇳Manobal Med. Research Centre, Lucknow, Uttar Prad, India
🇷🇴Spitalul Clinic Judetean de Urgenta Cluj, Cluj-Napoca, Romania
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2016-04-14
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 817
- Registration Number
- NCT00868959
- Locations
- 🇺🇸
Clinical Innovations Inc., Santa Ana, California, United States
🇺🇸Accurate Clinical Trials, Kissimmee, Florida, United States
🇺🇸Sheppard Pratt Health System, Baltimore, Maryland, United States
Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
- Conditions
- Epilepsy With Simple or Complex Partial Onset Seizures
- Interventions
- First Posted Date
- 2009-03-20
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 193
- Registration Number
- NCT00866775
- Locations
- 🇺🇸
Faculty of Physicians & Surgeons of Loma Linda University, Loma Linda, California, United States
🇺🇸Institute of Neurology and Neurosurgery at St. Bamabas, Suite 101, Livingston, New Jersey, United States
🇺🇸Massachusetts General Hospital Epilepsy Service - WACC, Boston, Massachusetts, United States
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
- Conditions
- InsomniaAttention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 304
- Registration Number
- NCT00857220
- Locations
- 🇺🇸
Clinical Research Center of Nevada, Henderson, Nevada, United States
🇺🇸Davis Clinic, Indianapolis, Indiana, United States
🇺🇸Goldpoint Clinical Research, LLC, Indianapolis, Indiana, United States
Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia
- Conditions
- InsomniaAttention Deficit Hyperactivity Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-03-06
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 486
- Registration Number
- NCT00856973
- Locations
- 🇺🇸
Tulsa Clinical Research, Tulsa, Oklahoma, United States
🇺🇸SomnoMedics, LLC, Tampa, Florida, United States
🇺🇸Pediatric Epilepsy and Neurology Specialists, Tampa, Florida, United States
A Safety, Efficacy and Tolerability Study in Pediatric Subjects With Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 197
- Registration Number
- NCT00809757
- Locations
- 🇺🇸
Dayton Clinical Research, Dayton, Ohio, United States
🇺🇸ADAC Research, PA, Greenville, South Carolina, United States
🇺🇸Sneeze, Wheeze & Itch Associates LLC, Normal, Illinois, United States
Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 488
- Registration Number
- NCT00790192
- Locations
- 🇺🇸
CNRI-Los Angeles. LLC, Pico Rivera, California, United States
🇺🇸Florida Clinical Research Center, Bradenton, Florida, United States
🇷🇴Spitalul de Psihiatrie Titan "Dr. Constantin Gorgos", Bdul Nicolae Grigorescu nr. 41, Bucuresti, Romania
Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT00789698
- Locations
- 🇺🇸
Florida Clinical Research Center LLC, Bradenton, Florida, United States
🇺🇸Pillar Clinical Research, Dallas, Texas, United States
🇮🇳Deenanath Mangeshkar Hospital and Research Centre, Pune, Maharastra, India